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Human hepatocyte chimeric miceHCV-JFH1 yields subclones that develop cytopathic plaques (Sekine-Osajima Y, et al., Virology 2008; 371:71).
Here, we investigated viral amino acid substitutions in cytopathic mutant HCV-JFH1 clones and their
characteristics in vitro and in vivo. The mutant viruses with individual C2441S, P2938S or R2985P signature
substitutions, and with all three substitutions, showed signiﬁcantly higher intracellular replication
efﬁciencies and greater cytopathic effects than the parental JFH1 in vitro. The mutant HCV-inoculated mice
showed signiﬁcantly higher serum HCV RNA and higher level of expression of ER stress-related proteins in
early period of infection. At 8 weeks post inoculation, these signature mutations had reverted to the wild
type sequences. HCV-induced cytopathogenicity is associated with the level of intracellular viral replication
and is determined by certain amino acid substitutions in HCV-NS5A and NS5B regions. The cytopathic HCV
clones exhibit high replication competence in vivo but may be eliminated during the early stages of infection.athic effect; ER, endoplasmic
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Hepatitis C virus (HCV) is one of the most important pathogens
causing liver-related morbidity and mortality (Alter, 1997). Antiviral
therapeutic options against HCV have been limited to type I
interferons and ribavirin and have yielded unsatisfactory responses
(Fried et al., 2002). Given this situation, a precise understanding of the
molecular mechanisms of interferon resistance has been a high
priority of research in academia and industry.
Molecular analyses of the HCV life cycle, virus–host interactions,
and mechanisms of liver cell damage by the virus are not understoodcompletely, mainly because of the lack of cell culture systems. These
problems have been overcome to some extent by the development of
the HCV subgenomic replicon (Lohmann et al., 1999) and HCV cell
culture systems (Lindenbach et al., 2005;Wakita et al., 2005; Zhong et
al., 2005). The HCV-JFH1 strain, which is a genotype 2a clone derived
from a Japanese fulminant hepatitis patient and can replicate
efﬁciently in Huh7 cells (Kato, 2001; Kato et al., 2003), has
contributed to the establishment of the HCV cell culture system.
Furthermore, the Huh7-derived cell lines, Huh-7.5 and Huh-7.5.1
cells, allow production of higher viral titers and have a greater
permissivity for HCV (Koutsoudakis et al., 2007; Lindenbach et al.,
2005; Zhong et al., 2005). The HCV-JFH1 cell culture system now
allows us to study the complete HCV life cycle: virus–cell entry,
translation, protein processing, RNA replication, virion assembly and
virus release.
HCV belongs to the family Flaviviridae. One of the characteristics of
the Flaviviridae is that they cause cytopathic effects (CPE). The viruses
have positive strand RNA genomes of ∼10 kilo-bases that encode
polyproteins of ∼3000 amino acids. These proteins are processed
post-translationally by cellular and viral proteases into at least 10
mature proteins (Sakamoto and Watanabe, 2009). The viral non-
structural proteins accumulate in the ER and direct genomic
replication and viral protein synthesis (Bartenschlager and Lohmann,
2000; Jordan et al., 2002; Mottola et al., 2002). It has been recently
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cells are infected and intracellular HCV RNA reaches maximum levels
(Zhong et al., 2006). These ﬁndings suggest HCV-induced cytopath-
ogenicity. However, themechanisms have not beenwell documented.
In a previous study, we investigated the cellular effects of HCV
infection and replication using the HCV-JFH1 cell culture system and
we reported that HCV-JFH1 transfected and infected cells show
substantial CPE that are characterized by massive apoptotic cell death
with expression of several ER stress-induced proteins. Taking
advantage of the CPE, we developed a plaque assay for HCV in cell
culture and isolated subclones of HCV that showed enhanced
replication and cytopathogenicity (Sekine-Osajima et al., 2008). We
have demonstrated that these viral characters were determined by
mutations at certain positions in the structural and nonstructural
regions of the HCV genome, especially the NS5A and NS5B regions.
In this study, we investigated the mechanisms and viral nucleotide
sequences involved in HCV-induced cytopathic effects using HCV-JFH1
cell cultureandanewlydeveloped cytopathic plaque-formingassay.We
demonstrated that introduction of NS5A and NS5B mutations into the
JFH1 clone resulted in a higher replication efﬁciency, although
introduction of these mutations into the JFH1 subgenomic replicon
has no effect on viral replication. These mutations do not affect virion
entry or release of viral particles but regulate virus replication, and high
levels of virus replication result in cytopathogenicity.Fig. 1. The cytopathic effects of HCV-JFH1 in vitro. A. Plaque assay. Huh-7.5.1 cells were see
were incubated at 37 °C under 5.0% CO2 (as described above). After overnight incubation, HC
and transferred onto the cell monolayers. After ∼5 h of incubation, the inocula were remo
methyl-cellulose and incubated under normal conditions. After 7 days culture, formation of
cytopathic plaques were observed by phase-contrast microscopy at day 7 after HCV-JFH1 inResults
Development of cytopathic plaques by HCV infection of Huh-7.5.1 cells
A plaque assay was performed to investigate the morphological CPE
following HCV-JFH1 infection (see Materials and methods). Culture
supernatants from JFH1-transfected cells were diluted serially and
inoculated onto uninfected Huh-7.5.1 cells. The cells were subsequently
cultured inmedium containing agarose. On 9 days after the inoculation,
viable cells were stained and plaques were visualized (Fig. 1A). HCV-
inoculated cell cultures developed plaques as unstained areas, accom-
panied by rounded cells in the periphery (Fig. 1B). The formation of
cytopathic plaques was not observed in a parental Huh7 cell line (data
not shown). Those results were consistent with our previous study
(Sekine-Osajima et al., 2008).
Introduction of mutations in the NS5A and NS5B regions of the JFH1
clone augmented its cytopathic effects
Among the amino acid substitutions that developed in the plaque-
derived HCV-JFH1 strains, 6 of the 9 amino acid changes appeared
redundantly among 5 independently isolated plaques, and clustered in
the C terminal part of the NS5A and NS5B regions. To investigate the
phenotypeof each amino acid substitution,we constructedmutant JFH1ded in collagen-coated 60mm-diameter plates at density of 4×105 cells per plates and
V-infected culture supernatants were serially diluted in a ﬁnal volume of 2 ml per plates
ved and the infected cells were overlaid with 8 ml of culture medium containing 0.8%
cytopathic plaque was visualized by staining with 0.08% crystal violet solution. B. The
fection.
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NS5A and ﬁve substitutions in NS5B (Fig. 2A) and transfected the
mutant HCV RNAs into Huh-7.5.1 cells. To compare the electroporation
efﬁciencies of viral RNAs, Huh-7.5.1 cells were harvested 8 h after
transfection and the levels of intracellular core antigen were measured.
There was no difference in the efﬁciencies of electroporation (Fig. 2D).
The substitutions G2964D, H3004Q, and S3005N did not lead to
cytopathic effects but three mutant subclones (C2441S, P2938S andFig. 2. Introduction of mutations into the NS5A and NS5B regions of JFH1. A. The mutations
Each JFH1 mutant was transfected into Huh-7.5.1 cells by electroporation. B. Huh-7.5.1 cells
after transfection. C. MTS assay was performed to assess the quantitative cytopathic effect se
p-values of less than 0.05 as compared with JFH1. D. Huh-7.5.1 cells were harvested at 8 hR2985P) produced much more cell death compared to the wild type
JFH1 (Fig. 2B). To assess the quantitative cytopathic effect seen in host
cells for eachof themutants,we alsoperformedMTSassay at 6 dayspost
transfection. It showed that Huh-7.5.1 cells transfected with the triple
mutants (C2441S, R2938S, or R2985P) induced apparently much more
cytopathic effect compared to the parental JFH1 and other mutant
clones, although the three mutant clones encoding the substitutions
C2441S, P2938S, or R2985P did not show signiﬁcant difference butidentiﬁed in the cytopathic plaque were introduced individually into the parental JFH1.
transfected with JFH1-mutants were observed by phase-contrast microscopy at day10
en in Huh-7.5.1 cells for each of the mutants 6 days post transfection. Asterisks indicate
after transfection and the levels of intracellular core antigen were measured.
Fig. 3. Replication competences of HCV subclones with NS5A and NS5B mutations.
A. Levels of core antigen in the culture medium. The culture media from transfected
cells were collected on the days indicated and the levels of core antigen were measured.
Asterisks indicate p-values of less than 0.05 as compared with JFH1. B. Huh-7.5.1 cells
transfected with JFH1 mutants were harvested at 5 days after transfection and western
blotting was performed. C. The culture media from Huh-7.5.1 cells transfected with
JFH1 mutants were transferred onto uninfected Huh-7.5.1 cells. The cells were
harvested at 3 days after infection. Western blotting was performed using anti-core
and anti-beta-actin. kDa: kilo dalton.
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JFH1 and the mutant clones encoding the substitutions G2964D,
H3004Q, and S3005N (Fig. 2C).
Introduction of NS5A and NS5B mutations into the JFH1 clone led to a
greater replication efﬁciency
To compare the expression levels of each mutant subclone, each
HCV RNA was transfected and core antigen was detected subsequent-
ly in the culture medium. Similar to Fig. 2B, HCV clones with
individual substitutions G2964D, H3004Q and S3005N produced
signiﬁcantly less core antigen or did not replicate at all. In contrast,
the C2441S, P2938S and R2985P mutants produced signiﬁcantly more
core antigen than the wild type JFH1. In addition, an HCV clone with
all 3 adaptive substitutions (C2441S, P2938S and R2985P) produced
more core antigen than any other clone (Fig. 3A).
Next, we harvested the infected cells at 5 days after electropora-
tion and performed western blotting. As shown in Fig. 3B, the three
clones encoding the substitutions C2441S, P2938S, or R2985P, and the
clone with all three mutations, expressed far more core protein than
the parental JFH1, although the clones encoding the substitutions
G2964D, H3004Q and S3005N did not express core protein. We also
transferred culture media from the mutant clones onto uninfected
Huh-7.5.1 cells and performed western blotting and the cells infected
with the same mutant subclones as Fig. 3B expressed more core
protein (Fig. 3C).
Introduction of NS5A and NS5B mutations into the JFH1 subgenomic
replicon
To investigate the primary phase of replication of JFH1 mutants,
we constructed JFH1 subgenomic replicons by introducing individu-
ally the sixmutations in NS5A and NS5B.We transfected each replicon
RNA into Huh7 cells and compared their replication levels according
to the luciferase activities. Consistently with the mutant viruses, the
subgenomic replicon encoding the changes C2441S, P2938S or
R2985P, which produced higher amounts of core antigen, did replicate
at higher levels than the other subgenomic replicons with single
mutation, G2964D, H3004Q and S3005N. However, none of these
mutants replicated athigher than theparental JFH1 subgenomic replicon.
Furthermore, replicon with triple mutations of C2241S, P2938S and
R2985P did not replicate (Fig. 4).
Introduction of NS5A and NS5B mutations into the JFH1 clone had no
effect on the production of infectious virions
We sought to investigate the effects of the NS5A and NS5B
mutations on virus replication and virion secretion independent of re-
infection and spread of the viruses produced. Therefore, we used the
S29-subclone of Huh7 cells, which cannot be infected by HCV because
of a defect in CD81 expression but does support viral genomic
replication and releases infectious HCV particles after transfection
(Russell et al., 2008). The Huh7-S29 cells enabled us to evaluate a
single cycle of infection and production of virions. Those cell lines did
not show apparent cytopathic effects after transfection with HCV
RNAs (data not shown). To analyze HCV particle production from cells
transfected with the viral genomic RNAs transcribed in vitro, we
harvested culture media and cells at 72 h post transfection and
measured the core antigen levels in culture media and intracellular
HCV RNA by real-time RT-PCR. The C2441S, P2938S, and R2985P
mutants produced signiﬁcantly greater amounts of core antigen in the
culture medium than the wild type JFH1. The HCV clone carrying all
three mutations produced the greatest amount of core antigen
(Fig. 5A, top). Consistent with the core antigen levels in the culture
media, intracellular HCV RNA levels were also higher in the cells
transfected with the mutated genomes encoding separately C2441S,P2938S, andR2985P, and thatwith all threemutations (Fig. 5A,middle),
indicating that thesemutations affected virus replication. Fig. 5Abottom
shows the efﬁciency of infectious viral particle release from each
transfectant, this being expressed as the core antigen level in the culture
medium adjusted by dividing by the levels of intracellular HCV RNA.
Therewas nodifference in the efﬁciency of release of virions by thewild
type JFH1 and the genomes carrying the C2441S, P2938S or R2985P
changes. These results indicated that these threemutations inNS5A and
NS5B did not affect virion entry or viral particle release but did regulate
virus replication, and a high level of viral replication induces
cytopathogenicity. Similarly, as shown in Fig. 3B, the three clones with
C2441S, P2938S or R2985P, or all three mutations expressed much
higher levels of core protein than the parental JFH1, while clones with
G2964D, H3004Q or S3005N mutations did not express detectable
amounts of core protein (Fig. 5B).
Fig. 4. Luciferase assay of the cytopathic JFH1-subgenomic replicon. Mutations were
introduced into 2a-Feo subgenomic replicon and transcribed RNA for each replicon was
transfected into Huh7 cells by electroporation. The cells were harvested at 24 h, 48 h
and 72 h after electroporation and were used for Luciferase assay. Values are relative
values to those of 8 h.
Fig. 5. Analysis of viral replication andproductionof viral particles using a single-cycle assay.
A. Levels of core antigen in the culture media 3 days after transfection of JFH1 mutants into
CD81-deﬁcient Huh7-S29 cells (top). Levels of intracellular HCV RNA were quantiﬁed by
real-time RT-PCR3 days after transfection of JFH1mutants into Huh7-S29 cells (middle). To
determine the efﬁciency of infectious viral particle release from Huh7-S29 cells transfected
with JFH1mutants, the levels of core antigen in the culturemediawere adjusted by dividing
by the levels of intracellular HCV RNA (bottom). Core Ag: Core antigen, N/D: not detectable.
B. Huh7-S29 cells were harvested at 3 days after transfection of JFH1 mutants and western
blotting was performed using anti-core and anti-beta-actin. kDa: kilo dalton.
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at earlier stages in vivo
We next used human hepatocyte chimeric mice to investigate the
infectivity of the triple mutant of NS5A and NS5B. We conﬁrmed the
mouse liver chimerism greater than 70% by immunohistochemical
analysis (data not shown). Culture media of the parental JFH1 and the
mutant subclone with three mutations (C2441S, P2938S, and
R2985P), were collected following transfection of Huh-7.5.1 cells,
concentrated, and inoculated intravenously into human hepatocyte
chimeric mice. We conﬁrmed that the three mutations in NS5A and
NS5B were conserved in the virus genome sequence of cell culture
supernatants that were used for inoculation (data not shown). Two
mice were inoculated with JFH1 and three were inoculated with the
mutant virus. HCV RNA and human albumin in the sera of the mice
were detected sequentially.
We repeated the same exam twice and conﬁrmed consistency of the
results. In the early phase post inoculation, the concentration ofHCVRNA
in serum was signiﬁcantly higher in mice inoculated with the culture
medium from the mutant subclone (Fig. 6A), suggesting that the muta-
tions in NS5A and NS5B (C2441S, P2938S, and R2985P) are associated
with virus replication in vivo. However, there was no difference in the
level of HCV RNA in later period. The disparity of viral production at early
time point could be inﬂuenced by the disparate numbers of infectious
virus between the 2 initial inoculums. However, the sharp elevation of
serum HCV RNA at day 5 after dropping at day 3 indicates that the
mutants (C2441S, P2938S plus R2985P) are more replication competent
at early stages in vivo. Serum levels of humanalbumin remained constant
throughout the observed periods and showed no signiﬁcant differences
between wild and mutant-infected mice (Fig. 6B).
We also investigated expression of ER stress-related proteins, the
glucose regulated protein 78 (GRP78) and C/EBP homologous protein
(CHOP), in liver of chimeric mice infected with JFH1 or the mutant in
the early phase post inoculation. Human hepatocyte chimeric mice
were inoculated in the same way as described above, and we veriﬁed
that the level of virus titer in serum of each mouse was same as
presented in Fig. 6A (data not shown). We sacriﬁced one each mouse
that was infected with wild type or mutant JFH1 at 5 day of infection
and investigated hepatic expression of GRP78 and CHOP. Liver
histology showed no sign of inﬂammation or cytopathic cell death.
However, as shown in Fig. 7, the expression level of both GRP78 and
CHOP was higher in mice inoculated with the mutant viruses than the
parental JFH1. There was no apparent difference in percents of hepatic
chimerism between each mouse. These ﬁnding suggested that ER
stress-related proteins were upregulated in the liver of HCV-infectedmouse and that these responses were more strongly induced in the
liver of mutant-infected mouse.
Highly adapted cytopathic mutations reverted to wild type in vivo
Finally, we analyzed the serum viral sequence at the speciﬁed time
points. On days 1 and 5, the HCV genomic sequences of the mice
Fig. 6. In vivo analysis of cytopathic JFH1mutants using humanhepatocyte chimericmice.
A. Serial changes in HCV RNA in the sera of mice inoculated with the culture media from
JFH1 mutants. The data shows the average of 2 mice for JFH1, and 3 mice for the mutant.
Asterisks indicate p-values of less than 0.05 as compared with JFH1. B. Levels of human
albumin in the sera of mice inoculated with the culture media from JFH1 mutants.
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the mutations in codons 2441, 2938 and 2985. However, on days 21
and later, the mutation at codon 2985 had reverted to the wild type
JFH1 sequence in all the mutant-injected mice and the mutation at
codon 2938 had reverted to the wild type JFH1 sequence in two of the
three mice. The C2441S mutation was more stable in the mutant-
injected mice, but one mouse had lost it at day 56 (Fig. 8).
Discussion
In this study,we investigated the signiﬁcance of geneticmutations in
plaque-puriﬁed, cytopathic HCV-JFH1 subclones. Genetically engi-Fig. 7. Expression of ER stress-related proteins in human hepatocytes of chimeric mice
infected with JFH1 or the mutant in the early phase. Western-blot analysis of the liver
tissues of infected chimeric mice using anti-GRP78 goat monoclonal antibody, anti-
GADD153/CHOP rabbit polyclonal antibody and anti-beta-actin. Liver samples were
obtained at 5 days after inoculation. The negative control liver samples for this study
was from uninfected human hepatocyte chimeric mouse.neered JFH1-mutants encoding C2441S, P2938S, and R2985P led to
much more cell death than the wild type JFH1, and also produced
signiﬁcantly higher amounts of core antigen in the culturemedium and
inside the cells than the parental JFH1 clone. In the single-cycle
production assay, which exploited a receptor-deﬁcient Huh7 cell line,
the three JFH1-mutants, JFH1-C2441S, P2938S, and R2985P produced
signiﬁcantly more core antigen in the culture medium and expressed
equivalently higher amounts of viral genomic RNA in the cells. These
data suggest that the three mutations in NS5A and NS5B (C2441S,
P2938S, andR2985P) are associateddirectlywithenhanced intracellular
replication and resultant virion formation, which correlated with the
extent of the cytopathic effects. Interestingly, inoculation of a
cytopathogenic mutant, JFH1-C2441S/P2938S/R2985P, into human
hepatocyte chimeric mice produced signiﬁcantly higher plasma HCV
RNA concentrations than JFH1 at ∼7 days post inoculation. At a later
phase of infection, however, the mutations in this mutant HCV reverted
partially to the wild type sequences. Taking all things together, it is
suggested that in vitro-isolated, genetically modiﬁed cytopathic HCV
subclones replicate robustly in the acute phase of in vivo infection but
are eliminated rapidly and substituted by in vivo adapted clones.
Four of the ﬁve NS5Bmutations appeared independently in several
isolated subclones. This made us speculate that these amino acid
substitutions may affect the enzymatic activity of RdRp. Mapping of
the amino acid substitutions in the RdRp tertiary structure revealed
that amino acid 2441 is located on the ﬁnger domain, and three amino
acids, 2938, 2964, and 2985, are on the outer surface of the thumb
domain, which corresponds to the opposite side of the nucleotide
tunnel. The other substitutions, 3004 and 3005, are within the domain
of the polypeptide linking the polymerase to the membrane anchor
(Lesburg et al., 1999). Our preliminary study has shown that the NS5B
mutations, P2938S and R2985P, did not affect cell-free enzymatic
activities of the RNA polymerase. Thus, it is speculated that these
mutations may affect the stability of the HCV replicase complex by
altering surface afﬁnity to other nonstructural proteins.
There are several reports on cell culture adaptive mutations in the
HCV-JFH1 genome that gave more vigorous and consistent virus
expression. Most studies involved prolonged cell culture of HCV-JFH1
or multiple rounds of successive passage onto naïve cells. Zhong et al.
detected the E2-G451R mutation after culture for more than 60 days.
The mutation led to more efﬁcient production of infectious viral
particles than wild type JFH1 (Zhong et al., 2006). Delgrange et al.
conducted successive virus infections of naïve cells and identiﬁed the
E2-N534K mutation that facilitated virus-CD81 attachment, and core-
F172C and -P173S that increased secretion of virions (Delgrange et al.,
2007). Using a similar method, Russell et al. identiﬁed E2-N417S that
improved virus–cell attachment, and p7-N765D and NS2-Q1012R that
increased virion production (Russell et al., 2008). Kaul et al. reported
the NS5A-V2440L mutation, that was close to the C terminus and
increased virion production (Kaul et al., 2007). Yi et al. used a chimeric
virus of genotype 1a and JFH1 and identiﬁed the NS3-Q1251L
mutation that resulted in enhanced virus production, possibly
through improved interactions between NS2 and NS3 that were
required for virion formation (Yi et al., 2002). Han et al. used EGFP-
tagged virus and identiﬁed the mutually dependent mutations, NS3-
M1290K and NS5A-T2438I, which improved virus production syner-
gistically (Han et al., 2009).
Of note is that all of the mutations reported above promoted virion
secretion or virus–cell surface interaction and none of them showed
any effect on intracellular replication of viral RNA or translation of
virus proteins. None of the adaptive mutations reported above
overlapped with our cytopathogenic mutations. The mutations that
we have identiﬁed conferred enhanced virus replication and protein
expression in the early/acute stages of infection and subsequently led
tomassive cell death. Our data and the reports of other groups suggest
that the HCV genome evolves to adapt to the host cell environment.
Mutations that optimize virus secretion or virus–cell entry may be
Fig. 8. Nucleotide sequence analysis of virus genomes circulating in the sera of infected mice. We extracted RNA from the sera of mice inoculated with culture media from JFH1 or
JFH1-mutants and analyzed the viral sequence at the speciﬁed time points. N/D is not detectable. Wt: Wild type.
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cellular viral RNA replication may possibly promote viral genetic
evolution and host cell damage.
The results of in vivo experiments using human hepatocyte
chimeric mice were consistent with those of virus cell culture
(Figs. 5, 6 and 7). The mutant JFH1 clones showed markedly higher
levels of replication than the parental JFH1 in the acute phases.
However, the serum HCV titers subsequently leveled out after two
weeks of infection, concomitant with reversal of some cytopathic
mutations to wild type sequences. Bukh et al. reported that
inoculation of the HCV-1b genome into chimpanzee liver resulted in
persistent infection, although the mutation reverted rapidly to wild
type (Bukh et al., 2002). In this study, the NS5A-C2441S mutation was
preserved in 2 of 3mice, while NS5B-P2938S reverted to the wild type
sequences in 2 of 3 mice and NS5B-R2985P reverted to wild type
sequences in all 3 mice. These results suggest that the highly adapted
JFH1 genome is infectious and viable in vivo, but is not as ﬁt in vitro.
It is not clear why the subgenomic replicons with C2441S, P2938S
or R2985P mutations did not show differences in replication levels
compared to the wild type JFH1 subgenomic replicon. One may
speculate that this discrepancy between the results using full-length
HCV genomes and replicons might be the presence or absence of the
HCV structural proteins. In addition, three individual substitutions
G2964D, H3004Q and S3005N did not enhance viral replication as
compared with the parental JFH1 nor did express detectable amounts
of core protein. It is speculated that these mutants exist in host cells
through co-infection with replication-competent viral clones result-
ing in enhanced replication.
There is clinical evidence that suggests the pathological outcomes
of hepatitis C result from the immune response of the host rather than
the direct cytopathic effects of the virus (Cerny and Chisari, 1999).
However, several clinical studies have shown that fulminant hepatic
failure (FHF, the HCV-JFH1 strain was isolated from such a case)
featured massive hepatocyte apoptosis, as characterized by caspase
activation and Fas–FasL expression (Leifeld et al., 2006; Mita et al.,
2005; Ryo et al., 2000). The ER stress markers, GRP78 and ATF6 are
upregulated in HCV-infected liver tissue as the histological grade
advances (Shuda et al., 2003). This background and our results in vitro
and in vivo suggest that HCV strains with highly infectious and
cytopathic gene signatures may replicate aggressively in the acute
phase of infection and that certain defects in innate or adaptive
immune responses against the virus could lead to severe and
persistent liver damage due to cytopathic effects induced directly byHCV. Such mechanisms might explain some rare clinical features of
HCV infection, such as fulminant hepatic failure and post-transplan-
tation severe ﬁbrosing cholestatic hepatitis (Delladetsima et al., 1999;
Dixon and Crawford, 2007).
In conclusion, we identiﬁed three substitutions in cytopathic HCV-
JFH1 subclones derived from plaque assay. These substitutions
directly enhanced virus replication in the early phases of virus
infection in vitro and in vivo. This highly enhanced replication
induced ER stress-mediated apoptosis and resulted in cytopathoge-
nicity. Further analyses of cellular effects on HCV replication may
elucidate the pathogenesis of HCV infection andmay deﬁne novel host
factors as targets of antiviral chemotherapeutics.Materials and methods
Cells and cell culture
Huh-7.5.1 cells (Zhong et al., 2005) (kindly provided by Dr Francis
V. Chisari) and CD81 deﬁcient Huh7-S29 cells (Russell et al., 2008)
(kindly provided by Dr Rodney S. Russell and Dr Robert H. Purcell)
were maintained in Dulbecco's modiﬁed minimal essential medium
(DMEM, Sigma, St. Louis, MO) supplemented with 2 mmol/L L-
glutamine and 10% fetal bovine serum at 37 °C under 5.0% CO2.Sequence analysis
The cDNA from the isolated JFH1-plaque was ampliﬁed from
cytopathic virus-infected Huh-7.5.1 cells by RT-PCR and subjected to
direct sequencing.In vitro RNA synthesis and transfection
A plasmid, pJFH1full (Wakita et al., 2005), which encodes full-
length HCV-JFH1 sequence, was used. In vitro RNA synthesis and
transfection were conducted as previously described (Sekine-Osajima
et al., 2008). Brieﬂy, HCV RNA was synthesized from linearized pJFH1
plasmid as template and transfected into Huh-7.5.1 cells by electro-
poration. The transfected cells were split every 3 to 5 days. The culture
media were subsequently transferred onto uninfected Huh-7.5.1 cells
and Huh7-S29 cells. The levels of HCV replication and viral protein
expression were detected by real-time PCR and western blotting.
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HCV plaque assays were performed as reported previously
(Sekine-Osajima et al., 2008). Huh-7.5.1 cells were seeded in
collagen-coated 60 mm-diameter plates. After overnight incubation,
HCV-infected culture media were serially diluted in a ﬁnal volume of
2 ml per plate and transferred onto the cell monolayer. After ∼5 h of
incubation, the inocula were removed and the cell monolayer was
overlaid with 8 ml of culture medium containing 0.8% methyl-
cellulose (Sigma). After 7 to 12 days culture, cytopathic plaques
were visualized by staining with 0.08% crystal violet solution (Sigma).
The levels of cytotoxicity were evaluated by counting the plaques and
calculating the titer (plaque-forming unit/ml).
Establishment of mutant JFH1 clones
In order to introduce various mutations into the NS5A and NS5B
region of JFH1, plasmid pJFH1 was digested with HindIII and the DNA
fragment encompassing nt. 8231 to 9731 was subcloned into the
pBluescript II SK+ phagemid vector (Stratagene, La Jolla, CA).
Mutations were introduced into the DNA fragment in the subcloning
vector by site-directed mutagenesis (Quick-ChangeII Site-Directed
Mutagenesis Kit, Stratagene) to generate the following codon
changes: P2938S, G2964D, R2985P, H3004Q and S3005N. Finally,
the HindIII–HindIII fragments were subcloned back into the parental
plasmid, pJFH1. A PCR fragment (nt. 7421–7839) was subcloned into
the pGEM-T Easy plasmid vector (Promega, Madison, WI) and
digested with RsrII and BsrGI. Finally, after introducing the codon
change C2441S, the RsrII–BsrGI fragment was reinserted into the
parental plasmid.
Quantiﬁcation of HCV core antigen in the culture medium
The culture media from JFH1-RNA transfected Huh-7.5.1 cells and
Huh7-S29 cells were collected on the days indicated, passed through a
0.45 μm ﬁlter (MILLEX-HA, Millipore, Bedford, MA), and stored at
−80 °C. The levels of core antigen in the culture media were
measured using a chemiluminescence enzyme immunoassay
(CLEIA) according to the manufacturer's protocol (Lumipulse Ortho
HCV Antigen, Ortho-Clinical Diagnostics, Tokyo, Japan).
Western blotting
Western blotting was carried out as described previously (Itsui
et al., 2009). Brieﬂy, 10 μg of total cell lysate were separated by SDS-
PAGE and blotted onto a polyvinylidene ﬂuoride (PVDF) Western
Blotting membrane. The membrane was incubated with the primary
antibodies followed by a peroxidase-labeled anti IgG antibody, and
visualized by chemiluminescence using the ECL Western blotting
Analysis System (Amersham Bioscience, Buckinghamshire, UK). The
antibodies used were anti-core mouse monoclonal antibody (Abcam,
Cambridge, MA), anti-GRP78 goat monoclonal antibody, anti-
GADD153/CHOP rabbit polyclonal antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), and anti-beta-actin antibody (Sigma).
HCV subgenomic replicon constructs
The HCV subgenomic replicon plasmid, pRep-Feo, was derived
from the HCV-N strain, pHCV1bneo-delS (Tanabe et al., 2004; Yokota
et al., 2003). The replicon RNA was synthesized from pRep-Feo and
transfected into Huh7 cells.
Luciferase reporter assay
Luciferase activity was measured using a 1420 Multilabel Counter
(ARVO MX, Perkin Elmer, Waltham, MA) with a Bright-Glo LuciferaseAssay System (Promega) (Tasaka et al., 2007). Assays were carried out
in triplicate and the results expressed as means±SD.
MTS assays
To evaluate cell viability, dimethylthiazol carboxymethoxy-phenyl
sulfophenyl tetrazolium (MTS) assays were performed using a
CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit
(Promega), as described previously (Sakamoto et al., 2007).
Real-time RT-PCR analysis
Total cellular RNA was isolated using an RNeasy Mini Kit (QIAGEN,
Valencia, CA). Two micro-grams of total cellular RNA were used to
generate cDNA from each sample using SuperScript II (Invitrogen)
reverse transcriptase. Expression of mRNA was quantiﬁed using
TaqMan Universal PCR Master Mix (Applied Biosystems) and the ABI
7500 Real-Time PCR System (Applied Biosystems). The primers used
were as follows: HCV-JFH1 sense (positions 285 to 307; 5′-GGT-
ACTGCCTGATAGGGTGCTT-3′), HCV-JFH1 antisense (positions 349
to 375; 5′-TGGTTTTTCTTTGAGGTTTAGGATTC-3′), GAPDH sense (5′-
CCTCCCGCTTCGCTCTCT-3′), and GAPDH antisense (5′-GCTGGCGACG-
CAAAAGA-3′).
HCV RNA inoculation into human hepatocyte chimeric mice
Housing, maintenance, and care of the mice used in this study
conformed to the requirement for the humane use of animals in
scientiﬁc research as deﬁned by Animal Care and Use Committee of
our institute. The culture media of Huh-7.5.1 cells transfected with
parental JFH1 and JFH1 mutants were collected 10 days after
transfection and passed through a 0.45 μm ﬁlter. The three mutations
introduced in NS5A and NS5B were conﬁrmed to conserve by the
sequence analysis of virus genome of cell culture supernatants before
inoculation. Filtrated culture medium was then pooled and concen-
trated using Amicon Ultra-15 (100,000 molecular weight cutoff,
Millipore). 100 μl of each culture medium was injected intravenously
into human hepatocyte chimeric mice (PXB mice, Phenix Bio,
Hiroshima, Japan) (Mercer et al., 2001). The rate of liver chimerism
of these human hepatocyte chimeric mice was conﬁrmed more than
70% by immunohistochemical analysis. After infection, blood samples
were taken serially and levels for HCV RNA and human albumin were
quantiﬁed using real-time RT-PCR and an enzyme immunoassay,
respectively. RNAwas extracted from serum samples and subjected to
direct sequence determination.
Protein extraction from human hepatocyte chimeric mice and expression
of ER stress-related proteins
5 days post inoculation, mice were sacriﬁced and proteins were
extracted from liver samples with complete Lysis-M Reagent Kit
(Roche Applied Science, Indianapolis, IN). One Mini Protease Inhibitor
Cocktail Tablet was dissolved into 10 ml of Lysis-M Reagent and 500 μl
of this ﬂuidwas added to 50 μg of each liver sample and homogenized.
The lysate was transferred to a microcentrifuge tube and centrifuged
at 14,000×g for 5 min. The supernatant containing soluble protein
was transferred to a new reaction tube and 20 μg of each protein was
used for western blotting to detect ER stress-related proteins.
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